VTGN traded 1 million shares on that news. Now it looks like they locked up biggest shareholders. Platinum Partners funded them early and took a big piece of the 10 million dollar underwriting last year after VTGN jumped to NASDAQ..I doubt anyone expected Platinum partners to implode.
When I met with CEO last year it was explained that the NIH originally funded for epilepsy and pain. The depression results were so promising they moved over and completely funded Phase 2a.
Depression is a blockbuster, AGN bought Naurex for about 600m up front with 1.2 billion dollars in backend payments after Phase 2b. Naurex is adjunctive treatment delivered through IV..
I see potential catalysts now of;
1. The US patents being issued
2. Phase 2B beginning
3. Phase 2A results
4. A new set of trials for Parkinson's and pain
This stock has not made any of the runups that most drug companies do during trials. Compare a 30 million market cap to the 600 mil plus 1.2 bil in Naurex deal.
Very promising, and fantastic upside.
News 
Market Data 
Discover 
